The University of Nevada, Las Vegas (UNLV) and Nevada Senator Harry Reid announced a five-year, $20.3 million grant awarded to UNLV from the National Institutes of Health (NIH) to lead a health research network of 13 universities across the Mountain West. The University of Nevada School of Medicine will partner on the grant.

HeartSine Technologies, the maker of Samaritan public access defibrillators, is voluntarily recalling its 300/300P devices because of a potential drain on batteries that could affect delivery of therapy in people experiencing sudden cardiac arrest.

Sanofi rescinded its New Drug Application with the FDA for lixisenatide, saying the decision was based on concerns about compromising its ELIXA cardiovascular study.

Congenital Heart Disease (CHD) is the No. 1 birth defect in the U.S., affecting nearly 40,000 of the nearly 4 million live births each year (J Am Coll Cardiol 2002;39[12]:1890-1900).

One pro football team’s decision to screen team members for heart disease has elevated awareness of cardiovascular health and sports, but it also raises questions about the effectiveness and cost-effectiveness of such approaches.

Sometimes breaking off the rear view mirror and starting down a new path is the way to go. That’s what Daniel Davis, MD, advocates when it comes to improving survival of cardiac arrest patients, preventing events and enabling better neurological outcomes. A unique resuscitative training program at the University of California San Diego (UCSD) has helped increase the survival rate of cardiac arrest to 47 percent—more than triple the national average—as well as decreasing the overall incidence of arrests through surveillance and a rapid response team. 

Dr. R. Clinton Webb, Chairman of the Department of Physiology at the Medical College of Georgia at Georgia Regents University, is the 2013 recipient of the American Heart Association Council on High Blood Pressure Research's Irvine Page-Alva Bradley Lifetime Achievement Award.

Black patients often have multiple risk factors for acute myocardial infarction (AMI), but secondary prevention efforts target white patients more often. In a study published in the Aug. issue of the Journal of Women’s Health, researchers found that black women bear the highest AMI risk factor burden, but are less likely to be prescribed preventive medications.